None
Conditions
Interventions
D1+S1:0.2 ug/kgDexmedetomidine+ET 0.5 v/v% sevoflurane
D1+S2:0.2 ug/kgDexmedetomidine+ET 1 v/v% sevoflurane
D1+S3:0.2 ug/kgDexmedetomidine+ET 2 v/v% sevoflurane
D1+S4:0.2 ug/kgDexmedetomidine+ET 4 v/v% sevoflurane
D2+S1:0.4 ug/kgDexmedetomidine+ET 0.5 v/v% sevoflurane
D2+S2:0.4 ug/kgDexmedetomidine+ET 1 v/v% sevoflurane
D2+S3:0.4 ug/kgDexmedetomidine+ET 2 v/v% sevoflurane
D2+S4:0.4 ug/kgDexmedetomidine+ET 4 v/v% sevoflurane
D3+S1:0.8 ug/kgDexmedetomidine+ET 0.5 v/v% sevoflurane
D3+S2:0.8 ug/kgDexmedetomidine+ET 1 v/v% sevoflurane
D3+S3:0.8 ug/kgDexmedetomidine+ET 2 v/v% sevoflurane
D3+S4:0.8 ug/kgDexmedetomidine+ET 4 v/v% sevoflurane
Sponsors
Department of Anesthesiology, Fuzhou General Hospital of Nanjing Military Region
Eligibility
Sex/Gender
Male
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 50 years old, Male or Female, palnned to received elective sugery with general anesthesia; 2. ASA stasus: I-II; 3. Planned length of stay >=24 h; 4. Informed consent was received by each study patient.
Exclusion criteria
Exclusion criteria: 1. Patients received premedicants before entering operation room; 2. Patients with difficult airway or suspected difficult airway; 3. BW 130% IBW, and BMI24 kg/m2; 4. Baseline HR < 60 bpm and/or with atrioventricular block; 5. Patients received muscle relaxant during intubation; 6. Patients with severe dysfunction of important organs; 7. Others.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Train of four stimulation; | — |
Secondary
| Measure | Time frame |
|---|---|
| End-tidal concentrations of sevoflurane; | — |
Countries
China
Contacts
Public ContactHuanghui Wu
Outcome results
None listed